Advances in Tardive Dyskinesia: A Review of Recent Literature


In the past three years, the U.S. Food and Drug Administration has approved two medications for tardive dyskinesia, contributing to a resurgent interest in recognition, management, and treatment.

This Psychiatric Times® supplement provides a brief review of primarily recent literature on tardive dyskinesia, including signs and symptoms, risk factors and epidemiology, potential mechanisms, and screening and treatment.

Download Supplement


Related Videos
Video 6 - "Future Perspectives on Schizophrenia Care"
Video 2 - "Pathophysiology of Narcolepsy and the Role of Orexins"
Video 1 - "Definition of Narcolepsy and Unmet Needs"
Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, experts on schizophrenia
Video 4 - "Physician Awareness of Cognitive Dysfunction in Schizophrenia"
Video 3 - "Insights on the Pathophysiology of Schizophrenia"
Video 2 - "Exploration into the Management of the Three Symptom Domains of Schizophrenia"
support group
© 2024 MJH Life Sciences

All rights reserved.